Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Transl Cancer Res
.
2019 Dec;8(Suppl 6):S618-S620.
doi: 10.21037/tcr.2019.06.28.
Authors
Alfonso Fiorelli
1
,
Fabiana Vitiello
2
,
Floriana Morgillo
3
,
Mario Santagata
4
,
Chiara Spuntarelli
4
,
Marina Di Domenico
5
,
Mario Santini
1
,
Andrea Bianco
6
Affiliations
1
Department of Translational Medical Sciences, Thoracic Surgery Unity, University of Campania "Luigi Vanvitelli", Naples, Italy.
2
Department of Pneumology and Oncology; Hospital Vincenzo Monaldi, Naples, Italy.
3
Oncology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
4
Maxillo and Oro-facial Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
5
General Pathology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
6
Department of Translational Medical Sciences, Pneumology Unity, University of Campania "Luigi Vanvitelli", Naples, Italy.
PMID:
35117144
PMCID:
PMC8799010
DOI:
10.21037/tcr.2019.06.28
No abstract available
Publication types
Editorial
Comment